Moreover, studies have indicated that PARP inhibition can deactivate GSK3 and upregulate PD-L1 in a dose-dependent manner, subsequently suppressing T-cell activation and enhancing cancer cell apoptosis, which might make this combination of target therapies potentially efficient in OCS patients (50). Here, CD274 is linked to cancer.